Cagrilintide + Semaglutide

Cagrilintide + Semaglutide is a dual-peptide combination featuring an amylin analogue and a GLP-1 receptor agonist. This combination is investigated for its synergistic effects on appetite regulation, glucose balance, and energy metabolism through the simultaneous activation of amylin and GLP-1 receptor pathways.

Cagrilintide, an amylin analogue, is being explored alongside semaglutide for its role in sustained weight management research. Amylin-related pathways are associated with satiety signalling in both homeostatic and reward-related brain regions. Semaglutide influences appetite regulation, insulin production, glucagon activity, and gastric emptying through GLP-1 receptor activation.

Ongoing clinical and laboratory studies continue to evaluate the potential of this combination for long-term metabolic and weight management applications.